Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > BUSINESS
BUSINESS
- Eisai Moves to Boost Global Use of Products via Emerging Market Businesses
May 8, 2014
- Suglat Tops Anterio’s "Mind Share" Ranking in GP Market in March; Xarelto Rises Sharply
May 8, 2014
- FDA Grants Priority Review to XTANDI for Add’l Indication: Astellas
May 8, 2014
- Takara Bio Submits IND Application for PII Study of Anticancer Agent HF10 to US FDA
May 8, 2014
- Drug Information Gained Mostly from Sales Reps, Less from Online Promotion: IMS Survey
May 8, 2014
- Nitto Denko Moving Ahead at Full Speed in Japan, US to Develop Nucleic Acid Drug as a Potential Cure for Cirrhosis
May 7, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
May 7, 2014
- Drug Makers’ Plans for MRs Becoming Clearer; Takeda to Bolster Force, Sanofi Making Big Reduction
May 7, 2014
- Ono, Nissan Chemical End Licensing Deal on Thrombocytopenia Agent
May 2, 2014
- Otsuka Granted European Approval for Multidrug-Resistant TB Medicine
May 2, 2014
- Oncolys Obtains Patent on Manufacturing Process for Anti-HIV Drug OBP-601 in Japan
May 2, 2014
- Nihon Chouzai Pharmaceutical Sales Reach 23,192 Million Yen in FY2013
May 1, 2014
- AZ Files for Domestic Approval of Bydureon Pen Formulation
May 1, 2014
- Chugai’s US Subsidiary Appoints Gianella-Borradori as Its Chief Medical Officer
May 1, 2014
- Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
- Daiichi Sankyo Ceases PIII Study of Nimotuzumab for Lung Cancer in Japan
April 30, 2014
- Takeda to Introduce New Performance-Based Incentive Programs for Board of Directors, Senior Execs
April 30, 2014
- Kissei Taps Morozumi as New President, COO
April 30, 2014
- Chugai Discontinues Multinational PIII of Onartuzumab for Lung Cancer
April 30, 2014
- Hisamitsu Begins PI of Transdermal Schizophrenia Treatment in US
April 30, 2014
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…